Related Experiment Video
Updated: Jul 23, 2026
12:43
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
Interdigitating dendritic cell sarcoma: a rare malignancy responsive to ABVD chemotherapy.
1Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD 21224, USA, USA.
Leukemia & Lymphoma
|August 3, 2002
Summary
Interdigitating dendritic cell sarcoma (IDCS) is a rare and aggressive cancer. A recent case study shows that ABVD chemotherapy can be an effective treatment, leading to a complete response.
Area of Science:
- Oncology
- Pathology
Background:
- Interdigitating dendritic cell sarcoma (IDCS) is an exceptionally rare and aggressive neoplasm, with fewer than 25 reported cases globally.
- Diagnosis is challenging due to its rarity and subtle histopathologic features, often confused with reticular cell tumors.
Observation:
- A 44-year-old female presented with abdominal pain and inguinal adenopathy, indicative of advanced IDCS.
- Staging revealed extensive inguinal, abdominal, and liver involvement, including a mass encasing the small bowel.
Findings:
- Morphologic, cytochemical, and immunohistochemical analyses confirmed the IDCS diagnosis.
- Immunohistochemistry was positive for CLA, Kp-1, and S-100, while negative for CD1a, CD3, CD20, CKER, and HMB45.
Implications:
- The patient achieved rapid clinical improvement and a complete response after six cycles of ABVD chemotherapy.
- This case suggests ABVD chemotherapy may be a viable and effective treatment option for interdigitating dendritic cell sarcoma, addressing the lack of consensus on therapeutic regimens.
